![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Aciex Therapeutics gets rights to develop Portola's Syk/JAK inhibitors for ophthalmic conditions
Executive Summary
Aciex Therapeutics Inc. (ocular drug candidates) has licensed exclusive global rights to develop Portola Pharmaceuticals Inc.’s (inflammatory conditions) small-molecule dual Syk/JAK inhibitors for topical ophthalmic conditions, including ocular allergy, dry eye, and inflammatory eye conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice